The Cooper Companies with ticker code (COO) have now 12 analysts covering the stock. The analyst consensus points to a rating of ‘Buy’. The target price ranges between 560 and 385 calculating the average target price we see 475.25. Now with the previous closing price of 408.41 this now indicates there is a potential upside of 16.4%. The 50 day MA is 399.28 and the 200 day moving average is 410.68. The company has a market cap of $20,349m. Visit the company website at: https://www.coopercos.com
The potential market cap would be $23,680m based on the market concensus.
The Cooper Companies, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment offers spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, myopia, ocular dryness and eye fatigues in the Americas, Europe, Middle East, Africa, and Asia Pacific. The CooperSurgical segment focuses on family and women’s health care, which provides medical devices, fertility, genomics, diagnostics, and contraception to health care professionals and patients worldwide. It offers surgical and office products, including PARAGARD, uterine manipulators, retractors, closure products, point of care products, LEEP products, endosee, and illuminate and fetal pillows; fertility products and services, such as fertility consumables and equipment, and embryo options and preimplantation genetic testing. The Cooper Companies was founded in 1958 and is headquartered in San Ramon, California.
